NICE Backing For Procolaran In CHF May Prove Lucrative For Servier
This article was originally published in The Pink Sheet Daily
Executive Summary
If NICE’s backing for Servier’s heart drug Procolaran does spread across Europe, then the resulting returns may offset some of financial pain the French group is set to feel in coming years.